Vitamin E Confirmed as Effective Treatment for Fatty Liver Disease
James Meschino, DC, MS, ROHP
Fatty Liver Disease is known medically as “steatohepatitis”, which involves inflammation and fat accumulation in the liver. It is often seen in alcoholics, but a form of the condition is also seen in non-alcoholic patients and labelled non-alcoholic steatohepatitis (NASH); NASH is also commonly seen in individuals with diabetes, obesity and metabolic syndrome (pre-diabetic state). Both forms of the condition can progress to cirrhosis.
Liver cirrhosis is a consequence of chronic liver disease whereby liver tissue is replaced by fibrosis, scar tissue and regenerative nodules, which together culminate into loss of liver function. Cirrhosis and chronic liver disease were the 10th leading cause of death for men and the 12th for women in the United States in 2001. Cirrhosis has a 10-year mortality of 34-66%, largely dependent on the cause of the cirrhosis. Alcoholic cirrhosis has the worse prognosis (1).
As a point of nutritional interest, a 2006 study suggested that coffee may help reduce risk of liver cirrhosis (Klatsky AL et al). The studies by AL Klatsky et al have shown that some yet unidentified constituent in coffee helps protect the liver from cirrhosis. This appears to be especially true in alcohol-induced cirrhosis injury. They also note that their studies suggest that coffee consumption is associated with a reduced risk of primary liver cancer known as hepatocellular carcinoma (not metastatic liver cancer) (2).
How Does Vitamin E Fit into the Story?
The updated practice guidelines from the American Association for the Study of Liver Diseases, the American College of Gastroenterology, and the American Gastroenterological Association, were released to medical doctors on August 3, 2012.According to these latest guidelines patients with NASH are encouraged to reduce excess body fat and avoid alcohol. One of the surprising recommendations includes providing these patients with 800 IU of vitamin E per day. Studies have shown that vitamin E reverses liver cell damage (histological features of liver cells) in cases of NASH. They state that Vitamin E supplementation (800 IU per day), therefore, should be considered as a first-line pharmacotherapy for this patient population. This is a crucial finding, as very few agents have been shown to actually reverse liver damage in cases of non-alcoholic steatohepatitis. As such, vitamin E is one of the interventions most likely to prevent progression to cirrhosis in these cases (1). Of note, too, is the recent finding that showed that vitamin E is also associated with reduced risk of liver cancer (hepatocellula carcinoma) in high-risk populations (3).
Absent from the recommendations from the American Association for the Study of Liver Disease, the American College of Gastroenterology, and the American Gastroenterological Association are other supplements, which have been shown to be helpful in cases of NASH and/or alcohol-induced fatty liver disease. The supplements for which there is the strongest evidence include:
- Milk Thistle – involving a standardized grade of silymarin (4.)
- Trimethylglycine (betaine) (5).
Other supplements may also be considered in the management of fatty liver disease, based on preliminary results and extensive animal experimentation. These best researched include:
- Picrorhiza (6).
- N-actetylcysteine (7,8).
To see the 2012 comprehensive clinical management guidelines for fatty liver problems refer to reference number 1 below.
Reference:
- http://gastroenterology.jwatch.org/cgi/content/full/2012/622/3
- Klatsky AL, Morton C, Udaltsova N, Friedman GD. 2006. “Coffee, cirrhosis, and transaminase enzymes”. Archives of Internal Medicine166 (11): 1190–5
- (http://jnci.oxfordjournals.org/content/early/2012/07/12/jnci.djs277).
- http://www.umm.edu/altmed/articles/milk-thistle-000266.htm
- http://www.umm.edu/altmed/articles/cirrhosis-000037.htm
- http://www.meschinohealth.com/books/picrorhiza
- http://www.ncbi.nlm.nih.gov/pubmed/17876880
- http://www.ars.usda.gov/research/publications/publications.htm?seq_no_115=213678